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ABSTRACT
The Beers’ criteria indicate that some anticholinergic drugs are inappropriate for treating elderly patients, but those most frequently
used anticholinergic drugs in previous studies. This study was aimed to explore the association between the potentially inappropriate
anticholinergic drugs (PIADs) and adverse outcomes among elderly people in Taiwan. A retrospective cohort study was conducted by
analyzing the Longitudinal Health Insurance Database (LHID2005) of the National Health Insurance Research Database (NHIRD) from
2007 to 2008 to investigate all prescriptions for elderly people above the age of 65. The anticholinergic risk scale (ARS) constituted the
criteria for PIADs. Adverse outcomes included emergency visits, hospitalization, and adverse drug reactions (ADRs) such as constipation,
delirium, cardiac arrhythmia, and cognitive impairment. The prevalence of PIADs was 18.67% in outpatient prescriptions. Approximately
75.65% of outpatients have received at least one PIAD. After adjusting for age, gender, the number of drug items, and CCI, patients, who
have received PIADs, had higher risks of emergency visits, hospitalization, constipation, delirium, and cardiac dysrhythmia (odds ratio
[OR] = 1.85, 1.07, 1.87, 1.51 and 1.16) than those who have never received PIADs. This study suggests that physicians should be cautious
when prescribing anticholinergic drugs for elderly patients to reduce the risk of adverse outcomes and improve the safety of medicating
elderly people.
Key words: elderly patients, potentially inappropriate anticholinergic drugs (PIADs), anticholinergic risk scale (ARS), adverse
outcomes, adverse drug reactions (ADRs)

INTRODUCTION
According to the Beers’ criteria, some previous studies
have revealed that potentially inappropriate medication
(PIM) is a risk factor for adverse drug reactions (ADRs)(1).
Those ADRs may cause an upset stomach, weariness, and
lethargy. Furthermore, more severe ADRs can even cause
falling, coma, emergency visit, and hospitalization. The
potentially inappropriate anticholinergic drugs (PIADs) with
anticholinergic properties pose a particular risk to elderly
patients, who are more susceptible to adverse anticholinergic
effects because acetylcholine levels decrease with advanced
age and typically reduce in patients with Alzheimer’s disease
and other forms of dementia(2). In particular, combining two
* Author for correspondence. Tel: +886-4-24739595 ext. 38140;
Fax: +886-4-23248155; E-mail: cshd015@csh.org.tw

or more drugs with anticholinergic properties may enhance
the risk of peripheral anticholinergic effects, such as dry
mouth, blurred vision, or an increased heart rate. Anticholinergic load can also induce severe central nervous ADRs,
ranging from sedation and confusion to delirium and cognitive impairment(2,3); which, in elderly patients, may often
go unrecognized. PIMs were identified using the published
Beers’ criteria(4), and medications with anticholinergic properties, other than those listed in the Beers’ criteria, were added.
The ability of an anticholinergic drug to cross the blood
brain barrier may antagonize muscarinic receptors in the
central nervous system. Medications with anticholinergic
properties have frequently been cited in relevant literatures
as causing an increase in ADRs(2,5-6). The primary ADRs of
anticholinergic drugs include falling down, dizziness, and
confusion, while eripheral ADRs include dry mouth, dry
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eyes, and constipation.
Anticholinergic toxicity, a common problem in elderly
people, is often the result of the cumulative anticholinergic
burden of multiple prescription medications, rather than of a
single compound. The use of anticholinergic drugs by people
with overactive bladder syndrome results in statistically
significant improvements in symptoms, and is associated
with a modest improvement in quality of life(7). However,
these ADRs are small in many cases, and mild ADRs are
common. Therefore, only a small proportion of patients are
satisfied with the effect of the treatment(8,9). A recent study
described that the proportion of individuals who remained on
continual treatment was approximately 50% after 3 months
from the initiation of treatment, and approximately 30% after
6 months(10). Approximately 20% of patients remained on
continuous treatment for more than one year. The relatively
low adherence may be related to the observation of limited or
no satisfaction with active treatment(8,9). Switching between
types of anticholinergic drugs does not seem to be a major
cause of the rather low adherence to treatment with a specific
product.
The cumulative effect of taking one or more drugs with
anticholinergic properties has been termed as “anticholinergic load”(11). Older people often take several medications
simultaneously to treat different comorbidities (so-called
polypharmacy), of which more than one may have anticholinergic effects(12). Because of high rates of polypharmacy,
elderly patients may be particularly susceptible to experiencing a high anticholinergic insult and load(13). ADRs
related to anticholinergic medication use can have negative
effects in older patients. The management of elderly patients,
particularly those suffering from dementia, should therefore
aim to reduce the use of medications with anticholinergic
effects(2). The objectives of this study were to investigate
the prevalence of anticholinergic drug use, as well as the
association between anticholinergic drug use and the adverse
outcomes. Moreover, this study included four ADRs, which
is more complete than previous studies.

METHODS
I. Data Source and Subjects
The National Health Insurance (NHI) program was
initiated in Taiwan in 1995, and covers nearly all inhabitants
(23,025,773 beneficiaries at the end of 2009, equivalent to a
99.6% coverage rate of all 23,119,772 inhabitants).
A retrospective cohort study was conducted by analyzing
the Longitudinal Health Insurance Database (LHID2005) of
the National Health Insurance Research Database (NHIRD)
from 2007 to 2008. The patients in this study aged 65 and
over, and prescriptions from dental departments, emergency
departments, and inpatient visits were excluded. The Anticholinergic Risk Scale (ARS) was the criteria for PIADs.
Prescription drugs that were topical, ophthalmic, otologic,
inhaled medication preparations, traditional Chinese

medicine, and related to dentistry were excluded from the
scope of our study. Adverse outcomes included emergency
visits and hospitalization, which excluded vehicular or other
accidents; ADRs included constipation, delirium, cardiac
arrhythmia, and cognitive impairment.
II. Study Design
This study was divided into three phases to achieve the
purpose of screening and analyzing study subjects in each
phase.
Phase I: January 2007 to June 2007 was the exclusion
period. Patients with any PIADs, hospitalizations or emergency visits were all excluded to ensure that all study subjects
were new cases without any PIADs, hospitalizations, emergency visits, or ADRs such as constipation, delirium, cardiac
arrhythmia, and cognitive impairment within six months
prior to the follow-up period.
Phase II: July 2007 to June 2008 was the observation
period of exposure and non-exposure groups. Patients with
at least one PIAD were classified into the exposure group
and were followed for six months, starting from the date of
medication prescription, to observe the occurrence of any
adverse outcomes such as emergency visits or hospitalization. In Phase II, by contrast, those who did not experience
any PIADs were classified into the non-exposure group and
were observed for the occurrence of any adverse outcomes.
Phase III: July 2008 to December 2008 was the followup period of observing any adverse outcomes. To ensure a
consistent follow-up period for each subject, subjects with
PIAD events during this period were excluded from the study
to prevent the occurrence of subjects with a follow-up period
less than 6 months at the end of the study.
III. Study Tools
(I) Anticholinergic Risk Scale, ARS
The ARS is a categorically ranked list of medications
for documenting the anticholinergic activity of various drugs,
and for predicting increased risks of adverse anticholinergic
effects in older patients (Table 1). These patients chosen in
this study, aged 65 and above, were exclusive of prescriptions of dental department, emergency department, and inpatient visits. Our study defined PIADs according to the ARS,
and topical, ophthalmic, otologic, and inhaled medication
preparations were excluded from the scope of our study. The
ARS is a tool for estimating the extent to which a patient may
be at risk of adverse anticholinergic effects that could lead to
constipation, cognitive impairment, cardiac dysrhythmia, and
delirium. The identified medications were ranked on a scale
of 0 to 3 points, according to anticholinergic potential(5).
(II) Charlson Comorbidity Index, CCI
This study used CCI scores to adjust the disease conditions of patients. The CCI included 19 comorbidity groups
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Table 1. Anticholinergic Risk Scale
3 Points
Amitriptyline hydrochloride
Atropine products
Benztropine mesylate
Carisoprodol
Chlorpheniramine maleate
Chlorpromazine hydrochloride
Cyproheptadine hydrochloride
Dicyclomine hydrochloride
Diphenhydramine hydrochloride
Fluphenazine hydrochloride
Hydroxyzine
Hydrochloride and
Hydroxyzine pamoate
Hyoscyamine products
Imipramine hydrochloride
Meclizine hydrochloride
Oxybutynin chloride
Perphenazine
Promethazine hydrochloride
Thioridazine hydrochloride
Thiothixene
Tizanidine hydrochloride
Trifluoperazine hydrochloride

2 Points

1 Point

Amantadine hydrochloride
Baclofen
Cetirizine hydrochloride
Cimetidine
Clozapine
Cyclobenzaprine hydrochloride
Desipramine hydrochloride
Loperamide hydrochloride
Loratadine
Nortriptyline hydrochloride
Olanzapine
Prochlorperazine maleate
Pseudoephedrine
Hydrochloride- triprolidine hydrochloride
Tolterodine tartrate

Carbidopa-levodopa
Entacapone
Haloperidol
Methocarbamol
Metoclopramide hydrochloride
Mirtazapine
Paroxetine hydrochloride
Pramipexole dihydrochloride
Quetiapine fumarate
Ranitidine hydrochloride
Risperidone
Selegiline hydrochloride
Trazodone hydrochloride
Ziprasidone hydrochloride

Source: Rudolph, J. L., Salow, M. J., Angelini, M. C. and McGlinchey, R. E. 2008. The anticholinergic risk scale and anticholinergic adverse
effects in older persons. Arch. Intern. Med. 168: 508-513.

and scores of 1, 2, 3, and 6 were assigned to each group to
represent the relative risk of mortality. The CCI also used age
to adjust the CCI score by adding 1 point per 10 years of age.
The higher the CCI score is, the severer the comorbidities
are(14).
(III) ICD-9-CM Code
The ADRs in this study were defined according to the
ICD-9-CM code; for instance, constipation (564), cognitive impairment (780.09), cardiac dysrhythmia (427.9) and
delirium (290-294).
IV. Statistical Analysis
Descriptive statistics were used to analyze the distribution of patient characteristics, PIADs, and adverse outcomes.
Chi-square and t tests were employed to analyze the correlation of the exposure and non-exposure groups with the
independent variables. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression models, controlling for patient characteristics, such as
gender, age, chronic disease, the number of drug items, and
CCI, to evaluate the association between PIADs and adverse
outcomes, where age was defined on July 1, 2007, and the
chronic diseases, number of drugs, and CCI measurement

Table 2. The distribution of potentially inappropriate anticholinergic
drugs in elderly population
Variables
Non-PIADs
PIADs

Prescriptions

Patients

n

%

n

%

2,037,620

81.33%

17,668

24.35%

467,753

18.67%

54,888

75.65%

1 point

88,890

17.28%

22,550

18.49%

2 point

235,181

45.73%

52,938

43.41%

190,192

36.98%

46,464

38.10%

2,505,373

100%

72,556

100%

3 point
Total

periods were all explained in the observation period (July
2007 to June 2008). Furthermore, the age, number of drug
items, and CCI were continuous variables in this study. All
statistical analyses were conducted using SAS 9.1.3 software
(SAS Institute, Cary, NC, USA).

RESULTS
In Table 2, the prevalence of PIADs was 18.67% in
outpatient prescriptions, but over 80% of PIAD prescriptions received 2-3 points. Approximately 75.65% of
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1.76-1.95) and hospitalizations (OR = 1.07, 95% CI: 1.011.13), as compared to those who have never received PIADs.
Other observed risk factors included gender (male compared
to female, OR = 1.13, 95% CI: 1.09-1.17), a higher number
of drug items (per one item increment, OR = 1.10, 95% CI:
1.08-1.11), and a higher CCI score (per one point increment,
OR = 1.38, 95% CI: 1.36-1.40) were associated with a higher
risk of emergency visits. In addition, chronic diseases were
associated with a higher risk of emergency visits (OR = 1.12,
95% CI: 1.06-1.18). Similar to emergency visits, gender (men
compared to women, OR = 1.15, 95% CI: 1.10-1.20), a higher
number of drug items (per one item increment, OR = 1.11,
95% CI: 1.09-1.12), and a higher CCI score (per one point
increment, OR = 1.56, 95% CI: 1.54-1.58) were also associated with a higher risk of hospitalizations.

outpatients have received at least one PIAD. An additional
comparison between PIAD and non-PIAD groups showed
that females accounted for 56.83 and 51.32%, respectively,
(p < 0.001) in these groups. The proportion of patients with
chronic diseases was 81.38 and 65.94% (p < 0.001) in the
PIAD and non-PIAD groups, respectively. Moreover, the
numbers of drug items and CCI in the PIAD group were
higher than those of the non-PIAD group (p < 0.001)
(Table 3).
In Tables 4 and 5, ORs and a 95% (CI) were estimated
using logistic regression models to examine the association
among PIADs, adverse outcomes, and ADRs. After adjusting
for gender, age, chronic disease, the number of drug items,
and CCI, elderly patients who have received PIADs were
at higher risk of emergency visits (OR = 1.85, 95% CI:

Table 3. The characteristics of elderly patients in the study
PIADs

Non-PIADs

n

%

Mean

SD

n

%

Mean

SD

p-value

female

31,192

56.83

-

-

9,067

51.32

-

-

<0.001

male

23,696

43.17

-

-

8,601

48.68

-

-

-

-

73.98

6.51

-

-

74.26

7.01

<0.001

Yes

44,669

81.38

-

-

11,651

65.94

-

-

<0.001

No

10,219

18.62

-

-

6,017

34.06

-

-

-

-

2.92

1.30

-

-

2.47

1.56

<0.001

-

-

4.13

1.64

-

-

3.67

1.42

<0.001

54,888

100

17,668

100

Gender

Age (years)*
Chronic disease

Number of drug items*
CCI (score)*
Total

* The continuous variables, such as age, number of drug items and CCI, were using t- test to analysis the difference of distribution.

Table 4. The relationship between potentially inappropriate anticholinergic drugs and adverse outcomes in elderly population
Variable

Emergency visit
n

OR

Hospitalization
95% C.I.

n

OR

2,111

1

1.76-1.95

9,177

1.07

95% C.I.

PIADs
No (ref.)

2,154

1

Yes

13,398

1.85

1.01-1.13

Gender
Female(ref.)

8,381

1

6,005

1

Male

7,171

1.13

1.09-1.17

5,283

1.15

1.10-1.20

15,552

1.01

1.00-1.01

11,288

0.996

0.99-1.00

No (ref.)

2,240

1

1,301

1

Yes

13,312

1.12

1.06-1.18

9,987

1.34

1.25-1.43

15,552

1.10

1.08-1.11

11,288

1.11

1.09-1.12

15,552

1.38

1.36-1.40

11,288

1.56

1.54-1.58

Age (years)
per 10 years increment
Chronic disease

Number of drug items
per one item increment
CCI (score)
per one point increment
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Beers’ criteria indicated that at least 12 to 21% of
patients aged 65 years or older in the U.S. have been
continually using PIADs(5). In the U.S., an estimated 51%
of the general population uses anticholinergic medications.
The reported prevalence of anticholinergic medication use
in a community-dwelling elderly population indicated a
range of 6.4 to 39%, thereby suggesting a high potential for
ADRs in this population(15). One report revealed that 60%
of elderly nursing home residents in the U.S. used at least
one anticholinergic medication, as compared with 23% of
the community-dwelling elderly population(16).
It is evident that the incidence of PIAD use in Taiwan far
exceeds that of the U.S. A. possible reason is that, after implementation of the NHI program in Taiwan, people experience
less financial burden in seeking medical services; therefore,
using health services increases. An increase in outpatient
visits (or in the number of drug items used) could offer
patients a higher chance of receiving PIAD prescriptions.
Elderly patients are particularly susceptible to the
dangers of polypharmacy, i.e., interactions between drugs
and ADRs. As the number of medications used by patients
increases, the incidence of ADRs increases exponentially(17).
A previous study showed that, when compared to patients
who use only one medication, those using 2 medications
concomitantly had a 13% risk of ADRs. The risk of ADRs
rose to 82% among patients concomitantly using 7 medications or more(18). The study results showed that the average
numbers of drug items used in the PIAD group was 4.34, and
was 2.29 in patients in the non-PIAD group. This finding is
consistent with a study in North America, that suggested that
the average number of drug items used by elderly people was

In the adverse outcome of emergency visits, the mean
follow-up times for exposed and unexposed groups were
90.55 and 144.64 days, respectively. Regarding hospitalization, the mean follow-up time was 88.45 days in the exposed
group and 155.17 days in the unexposed group. The relationship between PIADs and ADRs is shown in Table 5. After
adjusting for gender, age, chronic disease, the number of drug
items, and CCI, elderly patients who have received PIADs
were at higher risks for constipation (OR = 1.87, 95% CI:
1.72-2.03), delirium (OR = 1.51, 95% CI: 1.18-1.93) and
cardiac arrhythmia (OR = 1.16, 95% CI: 1.05-1.28); however,
the relationship was non-significant between cognitive
impairment and ADRs (OR = 1.29, 95% CI: 0.89-1.88).

DISCUSSION
In Taiwan, the incidence of PIAD use was 75.65% on
the “person” level, whereas the figure was 18.67% when
analyzing on the “prescription” level. This finding revealed
that the PIAD prevalence at the personal level is relatively
higher than that at the prescription level. This indicated that
the majority of elderly patients were subjected to PIADs,
albeit only on a few occasions. This may be the reason why
anticholinergic effects are caused by consuming various
drugs. Elderly patients belong to a population most likely to
have multiple chronic diseases; therefore, they have a higher
likelihood of experiencing PIADs. However, PIADs still
cause various ADRs. Thus, patients or physicians attempt to
avoid re-administering such drugs. This avoidance behavior
is what led to the significantly different results.

Table 5. The relationship between potentially inappropriate anticholinergic drugs and ADRs in elderly population
Variables

Constipation
n

O.R.

757

1

4,985

1.87

Female (ref.)

3,188

1

Male

2,554

1.06

5,472

1.04

592

1

5,150

1.77

5,472
5,472

95% C.I.

Delirium
95% C.I.

Cardiac arrhythmia

Cognitive impairment

n

O.R.

n

O.R.

503

1

34

1

2,272

1.16

185

1.29

1,627

1

n

O.R.

95% C.I.

95% C.I.

78

1

456

1.51

299

1

1.00-1.12

235

1.01

0.85-1.20

1,148

0.93

0.86-1.01

135

0.78

0.60-1.03

1.03-1.04

534

1.06

1.05-1.07

2,775

1.01

1.00-1.01

84

1.06

1.04-1.08

59

1

165

1

25

1

1.61-1.93

475

1.33

1.00-1.75

2,610

3.56

3.02-4.19

194

1.08

0.71-1.66

1.02

1.00-1.04

534

1.02

0.96-1.08

2,775

1.03

1.00-1.06

219

1.18

1.11-1.24

1.22

1.20-1.24

534

1.33

1.27-1.39

2,775

1.15

1.13-1.18

219

1.41

1.33-1.50

PIADs
No (ref.)
Yes

1.72-2.03

1.18-1.93

1.05-1.28

0.89-1.88

Gender
1

Age years
per 10 years increment
Chronic disease
No (ref.)
Yes
Number of drug items
per one item increment
CCI score
per one point increment
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4.5, and 40% of people were receiving one type of PIM(19).
Because most elderly people suffer from chronic diseases,
polypharmacy is common in this age group. An increase in
the number of used drug items leads to an elevated rate of
PIM use. This finding is consistent with previous studies that
indicated a higher relative risk of PIM use created by using a
greater number of drug items(19,20).
Emergency visits, hospitalization, and death are
common PIM-caused adverse outcomes(21,22). A previous
study showed that the incidence of emergency visits and
hospitalization of potentially inappropriate prescription in the
elderly (PIPE) was 10.86 and 8.12%, respectively; and the
relative risk of hospitalization attributable to PIPE was 1.62
times greater than that of non-PIPE(23). Lau et al. also indicated that the relative risk of hospitalization caused by PIMs
was 1.28(24). After controlling for covariates, the results of
this study showed that, as compared to the non-PIAD group,
the odds ratio of emergency visits in the PIAD group was
1.85, and the figure for hospitalization was 1.07. Although a
different study design and different samples were used, this
study concluded that PIADs and PIPEs yielded a higher risk
of adverse outcomes in patients. As a result, safety in patient
medication merits concern.
In the present study, after adjusting for covariates,
the relative risk of ADRs including constipation, delirium,
cardiac arrhythmia, and cognitive impairment in patients in
the PIAD group was higher than that in the non-PIAD group;
this finding is consistent with results from studies conducted
overseas. For instance, in a study conducted in nursing homes
in the U.S., elderly people taking anticholinergic drugs were
more likely to experience constipation than those who did
not(25). A strong association existed in 800 institutionalized
elderly people (average age, 84.7 years; range, 65 to 105
years) between the use of specific anticholinergic medications and constipation, as reflected in the increased use of
laxatives. Laxatives were used daily by 74% of the residents,
and 45% received more than one laxative a day(26). One study
revealed that cumulative anticholinergic exposure across
multiple medications over 1 year may negatively affect verbal
memory and executive function in older men(27). Another
study indicated a significant main effect of an anticholinergic
group, averaged over time for cerebral function with poorer
performance among anticholinergic medication users(28).
These findings are consistent with our results that cognitive
impairment in patients in the PIAD group was higher than
that in the non-PIAD group.
Previous studies have discovered that anticholinergic
drugs that create anticholinergic effects in the central neural
system could cause delirium and cognitive impairment(29,30).
Many studies have suggested that the use of anticholinergic
drugs among older people may be associated with delirium,
increased severity of dementia, falling, poor physical function, and cognitive impairment(31). Most importantly, the
reduction of anticholinergic medications may be a modifiable risk factor for avoiding associated morbidity. Given
the increased susceptibility to anticholinergic side effects
among older people, our study highlighted the need for the

routine assessment of possible anticholinergic ADRs among
this population. Further research is required to investigate
the possible association between anticholinergic drugs and
mortality, using alternative models and different populations.

CONCLUSIONS
This nationwide population-based study reveals that the
incidence of PIAD use among elderly patients in Taiwan is
much higher than that in the U.S.. In addition, after controlling for covariates, elderly patients who have received
PIADs were at higher risk of adverse outcomes including
emergency visits and hospitalization. Elderly patients were
also at higher risk of ADRs, including constipation, delirium,
cardiac arrhythmia, and cognitive impairment. The authors
hope that the results of this study could assist departments
related to geriatric medicine in Taiwan in establishing a decision-making model for the prescription of anticholinergic
medications, to reduce unnecessary PIAD prescriptions
and the associated adverse outcomes, which would further
improve the quality of health care and medication safety for
elderly patients.
There are some limitations in this study. First, when
a patient fails to demonstrate improvement or exhibit
intolerable effects under the treatment of first-line medication, prescribing medications that are considered inappropriate may become a viable clinical alternative. However,
prescribing potentially inappropriate medications cannot
replace thorough clinical diagnoses conducted by physicians and pharmacists. In addition, the ARS criteria do not
include the latest listing of new drugs and consider only
PIADs within the U.S.. However, despite the incompleteness
and limitations, the ARS criteria are still of great value in
reducing adverse outcomes in older patients. Second, lack of
medications purchased by the patients and patient’s physical
examinations or clinical laboratory tests (e.g., renal function)
because the LHID database was not allowed to link with
private medical records. Third, this study was not designed
to measure patients’ compliance or adherence. Whether the
patient followed the physician’s prescription could also alter
the risk of clinical adverse outcomes. Fourth, the CCI (which
was approved for predicting survival rates), re-admission
likelihood, and prognosis were used to control patients’
health status during this study. However, numerous critical
risk factors could not be measured, such as lifestyle. Fifth,
the state of adverse outcomes in this study, such as emergency visits and hospitalization, just excluded the events for
accidents that may not represented the actual situation. The
root causes should be explored in future studies. Finally, this
study investigated the prevalence of anticholinergic drug use
and its association with adverse outcomes. The factors influencing PIAD occurrence and the methods used to resolve the
patient and physician behavior as previously described are
not within the scope of this study. Future studies can analyze
and investigate these aspects.
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